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on outcome is homogeneous across the pooled trials. This issue, we chose all available studies and performed the
Mantel-Haenzel test in accordance with meta-analysisassumption can be tested statistically by the Q statistic.
Using data from the authors’ paper, we replicated their guidelines. We therefore decided to include the trial by
Neveu et al, especially because it was larger trial. Inanalyses. The calculated Q statistic was 13.0 (P  0.07),
indicating significant heterogeneity [2]. This suggests that addition, we report the results of our sensitivity analysis
by stratifying for methodology, which showed no benefita random effects model should be used, resulting in a
pooled odds ratio for mortality of 1.28, which is not statisti- with use of synthetic membranes; however, the direction
of the effect was the same and the statistical power wascally significant (95% CI, 0.86 to 1.92; P  0.15).
Even if a fixed effects model was used, meta-analyses obviously reduced by this subgroup analysis. Thus, while
using a random effects model may slightly alter the Pshould include observational studies only when random-
ized trials are impractical [3]. This suggests that the trial value it does not alter the size and direction of the effect.
The bulk of the evidence suggests a survival benefitby Neveu et al [author query: please cite Neveu et al in
reference] should be excluded, which results in a pooled with synthetic membranes over unsubstituted cellulose
membranes. More important, cellulosic membranes haveodds ratio for mortality of 1.11 (95% CI, 0.82 to1.50).
Since meta-analyses cannot replace single large, meth- never been shown to be superior to synthetic membranes
and in the absence of evidence to the contrary we thinkodologically rigorous randomized trials, their results are
only convincing when they are unchanged across a spec- at this point that use of synthetic membranes would be
trum of sensitivity analyses. As Subramania, Venkatara- a safe recommendation.
man, and Kellum [1] point out, the pooled odds ratio
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We appreciate the thoughtful comments of Tonelli Interestingly, plasma exchange might be beneficial to
et al regarding our meta-analysis. With regard to the both conditions, although therapy with calcineurin inhib-
use of a fixed effects model, we tested our studies for itors would greatly differ. We and others have found
heterogeneity and our Q statistic (Q  11.82 with P  that a regimen incorporating tacrolimus to be effective
0.1067) did not indicate significant heterogeneity. Thus, in reversing acute humoral rejection [3, 4], whereas with-
using a fixed effects model is not methodologically incor- drawal of calcineurin inhibitors, as discussed by Dr. Rug-
rect. However, we recognize the fact that there are obvi- genenti, would be essential in HUS thought to be due
ous apparent differences in the various studies and Table to these drugs.
1 in our report is structured so as to enable the reader
to examine these differences. In the absence of a large Colm C. Magee, Mark D. Denton, and Manuel Pascual
Boston, Massachusettsnumber of obviously homogenous studies addressing this
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Reply from the Authorindependently demonstrated that a deficiency in the activ-
Deficiency of von Willebrand factor-cleaving proteaseity of von Willebrand factor-cleaving metalloprotease,
(ADAMTS-13) activity should not be considered the soleADAMTS-13 or the presence of its inhibitory antibodies
criterion for administering plasma therapy to patients withcauses thrombotic thrombocytopenic purpura. It is un-
thrombotic microangiopathies (TMA). Actually most pa-known whether a similar mechanism occurs in patients
tients with different forms of TMA, including geneticwho develop thrombotic microangiopathy (TMA) follow-
forms associated with factor H deficiency, referred to theing organ transplantation. We have recently shown that
Italian Registry for Recurrent and Familial hemolytic ure-the ADAMTS-13 activity was undetectable in plasma
mic syndrome (HUS) and thrombotic thrombocytopenicsamples obtained from a patient who developed TMA
purpura (TTP) responded to plasma therapy [1], regard-after receiving a cadaveric renal allograft. Deficiency of
less of ADAMTS-13 activity. Thus, restricting plasma in-the protease enzyme occurred in the presence of its inhibi-
fusion or exchange to cases with congenital or acquiredtory antibodies. Discontinuation of cyclosporine and daily
deficiency of ADAMTS-13 activity would deprive someplasma exchange raised the ADAMTS-13 activity, fol-
TMA patients of the only potentially effective treatment.
lowed by resolution of the microangiopathic hemolysis
Moreover, assays of ADAMTS-13 activity are lengthy
and improvement of the graft function [3]. and available only in specialized reference laboratories.
Ruggeneti [4] pointed out in an article recently pub- Thus, plasma therapy should be decided on the basis of
lished in Kidney International that restoration of von clinicopathologic observations [2]. Samples for later de-
Willebrand factor-cleaving protease activity in parallel termination of ADAMTS-13 activity could be collected
with disease remission does not necessarily imply that before plasma therapy is started. The activity level may
normalization of the protease activity is the determinant influence subsequent therapeutic decisions [3]. Sporadic
of response to plasma. We are curious if this is based forms, including posttransplant TMA, are often precipi-
on case studies or solely speculations. In our case, we tated by drugs. In these forms, drug discontinuation and
showed that the ADAMTS-13 activity rapidly increased plasma exchange usually rise ADAMTS-13 activity and
to 50% or higher after two sessions of plasmapheresis. remove the inhibitors. In recurrent forms with congenital
We further showed that the immunoglobulin G (IgG) ADAMTS-13 deficiency, plasma induces disease remis-
molecules isolated from the patient’s plasma inhibited sion even before, or without, normalizing ADAMTS-13
the ADAMTS-13 activity in normal plasma. During activity [4]. In forms with continuous formation of the
disease remission, the IgG molecules isolated from the inhibitor, we and others have seen that the antibody titer
patient’s plasma showed no inhibitory effect on the decreases immediately after treatment, but returns to
ADAMTS-13 activity in normal plasma. We speculate pretreatment values shortly after stopping plasma, after
in cases that do not recur [4].that plasma exchange confers its effectiveness by replen-
